- Current report filing (8-K)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 7, 2009 (December 5, 2009)

 

ALLOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		000-29815		54-1655029
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

 

11080 CirclePoint Road, Suite 200 Westminster, Colorado		80020
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

Section 8 — Other Events

 

Item 8.01               Other Events.

 

On December 5, 2009, Allos Therapeutics, Inc. (the “Company”) issued a press release announcing new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN TM  (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).  The Company also reported preliminary results from its Phase 1/2 study of FOLOTYN in combination with gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies and certain other data presented during poster sessions at the 51 st  Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.  The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Section 9 — Financial Statements and Exhibits

 

Item 9.01               Financial Statements and Exhibits.

 

(d)           Exhibits

 

99.1

Press Release, dated December 5, 2009, entitled “Allos Therapeutics Reports New Analyses from Pivotal PROPEL Trial of FOLOTYN TM  at 51 st  ASH Annual Meeting.”

 

2

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  December 7, 2009
		ALLOS THERAPEUTICS, INC.
	By:	/s/ Marc H. Graboyes
		Marc H. Graboyes
	Its:	Senior Vice President, General Counsel and Secretary

 

3

---

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press Release, dated December 5, 2009, entitled “Allos Therapeutics Reports New Analyses from Pivotal PROPEL Trial of FOLOTYN TM  at 51 st  ASH Annual Meeting.”

 

4

---